Abstract:Mohsen Salama, &ast Nehad Darwesh, &ast Maha Mohammad Elsabaawy, &ast Eman Abdelsameea, &ast Asmaa Gomaa, &ast Aliaa Sabry &ast Department of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egypt &astThese authors contributed equally to this work Correspondence: Asmaa Gomaa, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egypt, Tel +20-1006157160, Email Purpose: This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens. Patients and Methods: This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up. Results: About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin ( P = 0.001), liver enzymes ( P = 0.001), alpha-fetoprotein (AFP) ( P < 0.001), platelet count ( P = 0.001), the model for end-stage liver disease (MELD) score ( P = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores ( p < 0.001). The liver stiffness (LS) also significantly improved ( p = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation ( p = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development. Conclusion: Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis. Keywords: long-term outcomes, cirrhotic patients, sustained virological response, DAAs Chronic infection with hepatitis C virus (HCV) persists as a significant universal public health issue, which affects almost seventy-one million individuals who are persistently infected with HCV. 1 Chronic inflammation of the liver causes fibrosis, which can eventually develop into cirrhosis. This increases the vulnerability of individuals to hepatic decompensation, HCC, and mortality related to hepatic disease. 2,3 During the interferon (IFN) era, achieving SVR was linked to better long-term results and a reduced risk of liver-related diseases, such as HCC. 2 However, even the most efficient IFN therapy plans were hindered by extended periods of treatment, significant adverse effects, and limited effectiveness in combating the virus. Furthermore, the primary determinant is the likelihood of achieving positive therapeutic outcomes in individuals with advanced liver disease for whom IFN-based treatment may not be suitable. 4 The implementation of IFN-free DAAs has significantly increased SVR rates in all patient groups, including those with severe liver disease or prior treatment experience, consequently altering the progression of chronic HCV infections. The SVR rates achieved with DAA regimens surpass 95%, demonstrating an outstanding safety and tolerability profile. This has expanded the range of individuals eligible for HCV treatment, along with those who have successfully been cured. 5–9 Noteworthy, Egypt has shifted from having the highest rates of HCV infection globally to one of the lowest by lowering the prevalence from 10% to 0.38% in just over a decade. It has diagnosed 87% of inhabitants having chronic hepatitis C and offered treatment to 93% of those diagnosed and was awarded the "gold tier" status on the path to elimination of hepatitis C, as per WHO criteria. The treatment was offered to a large number of patients including those with advanced liver disease and cirrhosis, which raised attention about the long term consequences on those patients, especially decompensation events and risk of HCC. 10 Research on the immediate effects of DAA therapy in advanced liver disease patients has shown enhancements in the MELD score and other biochemical markers of liver function. 11–14 Nevertheless, it remains unclear how the elimination of a virus and potential improvements in liver function may be connected to the development of long-term clinical outcomes in real-w -Abstract Truncated-

Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy

Long-term Outcomes in Patients with Chronic Hepatitis C in the Current Era of Direct-Acting Antiviral Agents

Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study

A retrospective follow-up study of hepatitis C virus related cirrhosis treated with direct-acting antiviral agent

The Burden of Chronic Hepatitis C in China from 2004 to 2050: an Individual‐Based Modeling Study

Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection

Efficacy and Safety of Combined Directly Acting Antivirals for Treatment of Chinese Chronic Hepatitis C Patients in a Real-World Setting

Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan

Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections

DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C

Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients

Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study

Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R)

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon Versus Direct-Acting Agents

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?

Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs)

Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings